Next-Generation Infection Treatment and Prevention Platform
Legal Citation
Summary of the Inventive Concept
A paradigm-shifting platform integrating AI-driven personalized treatment regimens, real-time mutation monitoring, and quantum computing-based simulation for optimal anti-microbial therapies, revolutionizing infection treatment and prevention.
Background and Problem Solved
The original patent addressed the need for effective infection treatment and prevention methods. However, the rise of vaccine breakthrough infections and mutant strains necessitates a more forward-thinking approach. The new inventive concept addresses these limitations by leveraging cutting-edge technologies to create a more proactive and adaptive system.
Detailed Description of the Inventive Concept
The platform comprises four key components: (1) a machine learning-based predictive model identifying potential mutant strains, (2) a personalized, AI-driven treatment regimen combining anti-microbial drugs with vaccines, (3) a real-time monitoring device detecting genetic mutations in infectious agents, and (4) a quantum computing-based simulation platform predicting optimal therapeutic strategies. These components work in tandem to prevent vaccine breakthrough infections, optimize vaccine efficacy, and develop novel anti-microbial therapies.
Novelty and Inventive Step
The new claims introduce a quantum leap in infection treatment and prevention by integrating AI, machine learning, and quantum computing to create a proactive, adaptive system that addresses the limitations of the original patent. The inventive step lies in the synergistic combination of these technologies to prevent vaccine breakthrough infections and optimize therapeutic strategies.
Alternative Embodiments and Variations
Alternative embodiments may include using different AI algorithms, integrating additional data sources, or adapting the platform for specific infectious agents. Variations could include developing mobile apps for real-time monitoring or creating decentralized networks for data sharing and collaboration.
Potential Commercial Applications and Market
The next-generation infection treatment and prevention platform has vast commercial potential in the healthcare and biotechnology industries, particularly in the areas of vaccine development, infectious disease treatment, and personalized medicine.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/12 |
| A | A61 | A61K31/166 |
| A | A61 | A61K45/06 |
| A | A61 | A61P31/14 |
| C | C12 | C12N7/00 |
| A | A61 | A61K2039/545 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical biotechnology focused on infectious disease treatment, specifically vaccine development, anti-microbial therapies, and personalized medicine interventions involving immunological and pharmaceutical approaches
Person of Ordinary Skill (PHOSITA) Profile
A medical researcher or biotechnology professional with advanced degrees (PhD/MD) in virology, immunology, or pharmaceutical sciences, possessing expertise in drug development, vaccine design, computational biology, and understanding of emerging technologies like machine learning and predictive modeling
Obviousness Rationale
A PHOSITA would recognize that the PTD represents a predictable technological progression from the source patent by applying known computational techniques to enhance existing infection treatment methodologies. The integration of AI, machine learning, and quantum computing represents an incremental improvement in personalized medical treatment strategies that would be obvious to a skilled practitioner seeking to optimize therapeutic interventions.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,617 |
|---|---|
| Title | Methods for treating, ameliorating or preventing infections using drug and vaccination combination treatment |
| Assignee(s) | TOPELIA AUST LIMITED (652 771 670) |